In the Olympus vs Boston Scientific endoscopy race, Olympus holds the top share of the global gastrointestinal (GI) endoscopic device market, while Boston Scientific leads more device segments than any rival.
The three largest global GI endoscopic device companies are Olympus, Boston Scientific and Fujifilm, based on iData Research market share data for 2025.
In the U.S. GI endoscopic device market, Boston Scientific ranks ahead of Olympus, placing second behind Exact Sciences, now part of Abbott.
This guide compares the two companies across the global market, the U.S. market and single-use endoscopes.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who leads endoscopy in 2026, Olympus or Boston Scientific
➜ Why Olympus leads the global GI endoscopy market
➜ What makes Boston Scientific endoscopy a segment leader
➜ Who ranks higher in the U.S. GI endoscopic device market
➜ How Olympus and Boston Scientific compare in single-use endoscopes
➜ How big is the GI endoscopic device market
Key Takeaways
- Olympus held the leading share of the global GI endoscopic device market in 2025, with Boston Scientific second and Fujifilm third.
- Boston Scientific led more global segments than any competitor, including stenting, ERCP, EUS needles and hemostasis.
- In the U.S. GI endoscopic device market, Boston Scientific ranked second and Olympus ranked third, behind Exact Sciences.
- Olympus ranked first and Boston Scientific second in the U.S. single-use and reusable endoscope market.
- iData Research values the global GI endoscopic device market at nearly $16.3 billion in 2025, growing at a 4.0% CAGR.
Who leads endoscopy in 2026, Olympus or Boston Scientific
Olympus leads endoscopy overall, holding the top share of the global GI endoscopic device market in 2025.
Boston Scientific ranks second globally, but it leads more market segments than any other competitor.
The order flips in the U.S. GI endoscopic device market, where Boston Scientific ranks second and Olympus ranks third.
In the U.S. single-use and reusable endoscope market, Olympus ranks first and Boston Scientific ranks second.
Why Olympus leads the global GI endoscopy market
Olympus holds the top spot because it leads the GI endoscope segment, the core of the market.
According to iData Research, Olympus also led the global endoscopic submucosal dissection (ESD) knife segment in 2025.
It kept strong shares in capsule endoscopy, ERCP devices, biopsy forceps, polypectomy snares, EUS needles and hemostasis devices.
iData credits its lasting scope leadership to a reputation for high-quality, reliable devices.
In July 2025, Olympus launched the EU-ME3 ultrasound processor in the U.S., combining EUS and EBUS on one platform.
That same month, Olympus and Revival Healthcare Capital co-founded Swan EndoSurgical to develop an endoluminal robotic system for GI care.
In January 2026, Olympus launched the SecureFlex single-use fine needle biopsy device for EUS-guided biopsy in the U.S.
In February 2026, it reported EAGLE trial results showing its CADDIE AI solution improved detection of high-risk and hard-to-detect colorectal lesions.
In March 2026, Olympus launched the VISERA ELITE III surgical imaging platform in the U.S.
In May 2026, Olympus and Canon introduced the Aplio i800 EUS ultrasound system in the U.S.
Olympus also faces regulatory pressure, as the FDA placed import restrictions on some Olympus endoscopes and accessories in June 2025 over quality system violations.
What makes Boston Scientific endoscopy a segment leader
Boston Scientific’s strength lies in the therapeutic devices passed through the scope.
In 2025, the company held the top global share in stenting and dilation, ERCP devices, biopsy forceps and polypectomy snares, EUS needles and hemostasis devices.
That made Boston Scientific the leader in more GI device segments than any other company, according to iData Research.
In GI endoscopes, it ranked third globally behind Olympus and Fujifilm.
iData expects strong growth for its AXIOS lumen-apposing stent and its EXALT Model D single-use duodenoscope.
The Boston Scientific endoscopy business is also growing quickly.
On April 22, 2026, the company reported first-quarter endoscopy sales of $736 million, up 9.4% from $673 million a year earlier.
A 2026 meta-analysis in the Journal of Gastroenterology and Hepatology found that crossover from EXALT Model D to a reusable duodenoscope occurred in 7% of cases.
The same review supports single-use scopes mainly for duodenoscopes and high-infection-risk patients rather than full replacement of reusable scopes.
Who ranks higher in the U.S. GI endoscopic device market
In the U.S., Boston Scientific outranks Olympus in total market share.
iData Research valued the U.S. GI endoscopic device market at nearly $7.6 billion in 2025.
Exact Sciences ranked first, driven by its Cologuard FIT-DNA test and the newer Cologuard Plus.
Abbott completed its acquisition of Exact Sciences in March 2026, so the top slot now sits inside Abbott.
Boston Scientific ranked second, leading U.S. stenting and dilation, ERCP, biopsy forceps, polypectomy snares, EUS needles and hemostasis devices.
Olympus ranked third, although it led the U.S. GI endoscope and ESD knife markets.
The U.S. report includes FIT-DNA tests and a wider device scope, which is why its order differs from the global ranking.
For more on what shapes U.S. demand, see our analysis of gastroenterology market trends.
How Olympus and Boston Scientific compare in single-use endoscopes
Olympus ranked first in the U.S. single-use and reusable endoscope market, which iData Research valued at $3.16 billion in 2025.
Its lead rests on large reusable categories, including GI endoscopes and reusable hysteroscopy.
Boston Scientific ranked second, and Ambu ranked third.
iData attributes Boston Scientific’s position mainly to its leadership in single-use GI endoscopy, including duodenoscopy and pancreaticobiliary visualization.
Boston Scientific also leads the U.S. urological scope segment, helped by fast-growing single-use ureteroscopes.
In its April 2026 results, Boston Scientific reported FDA 510(k) clearance for the Asurys Fluid Management System, designed for use with its LithoVue Elite single-use ureteroscope.
iData describes Boston Scientific as one of the companies most exposed to the shift toward single-use endoscopy.
Adoption is still gradual, as an Indiana University study found single-use duodenoscopes rose from 2.6% of ERCPs in 2020 to 4.7% in 2023.
Read more in our look at how single-use endoscopes drive urological endoscopy growth.
How big is the GI endoscopic device market
iData Research valued the global GI endoscopic device market at nearly $16.3 billion in 2025.
It is forecast to grow at a CAGR of 4.0% to reach over $21.2 billion.
The U.S. market is forecast to grow faster, at a CAGR of 5.6%, to reach $10.9 billion.
Expanding colorectal cancer screening eligibility is driving demand in both reports.
Specialist shortages and pricing pressure remain the main limits on growth.
Full rankings, segment shares and forecasts are in the Global GI Endoscopic Device Market report.
Frequently asked questions
Is Olympus bigger than Boston Scientific in endoscopy?
Yes, Olympus held the top share of the global GI endoscopic device market in 2025, and Boston Scientific ranked second.
What is Boston Scientific endoscopy known for?
Boston Scientific is known for the AXIOS stent, the EXALT Model D single-use duodenoscope and leading shares in stenting, ERCP, EUS needles and hemostasis devices.
Who is the largest GI endoscope manufacturer?
Olympus led the global GI endoscope segment in 2025, followed by Fujifilm and Boston Scientific.
Who leads the U.S. GI endoscopic device market?
Exact Sciences, now owned by Abbott, led the U.S. market in 2025, followed by Boston Scientific and Olympus.
How fast is the GI endoscopic device market growing?
The global market is growing at a CAGR of 4.0%, and the U.S. market at a CAGR of 5.6%.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
